<DOC>
	<DOC>NCT00350779</DOC>
	<brief_summary>A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin/peroxisome proliferator-activated receptor gamma (PPARg) agonist combination therapy.</brief_summary>
	<brief_title>Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Glipizide</mesh_term>
	<criteria>Patient has type 2 diabetes mellitus Patient is inadequately controlled while taking two oral antidiabetic medications Patient has a history of type 1 diabetes mellitus or history of ketoacidosis Patient required insulin therapy within the prior 3 months Patient has been taking Byetta (R) (exenatide) within the prior 3 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
</DOC>